Europe The European Commission has set itself an ambitious target: making Europe the world’s most attractive destination for life sciences by 2030. In recent conversations with PharmaBoardroom, executives leading Europe for AbbVie, BeOne Medicines, CSL, Merz Therapeutics, and Novartis would love to see this realised and agree that Europe’s scientific fundamentals…
Germany Innovation, supply security, and sustainability are intertwined challenges for healthcare systems across Europe. For CSL, these conversations are part of everyday reality, from ensuring access to plasma-derived therapies and advancing treatments for rare diseases to navigating an evolving policy landscape in one of its most important markets. Annegret Wittich-Hoeffer, Cluster…
Europe Europe’s position as a global healthcare leader is being tested by intensifying competition from both the US and China. As CSL’s Dirk Hoheisel points out, this is not because Europe lacks scientific excellence, industrial strength, or innovative capacity, but – in his opinion – due to a fragmented system that…
Europe Europe has a plasma problem. The continent is over-reliant on the US for plasma – donated, purified human blood liquid – which is a key component in several lifesaving drugs for immunity, bleeding, critical care, and rare disorders. The Donor Dilemma One explanation for these shortages is the lack…
Global The CGT field is undergoing a critical transformation from boom to thoughtful reset. While early enthusiasm brought a rush of investment and regulatory attention, the sector is now refining its ambitions, weeding out unviable approaches, and laying the foundations for long-term impact. Companies, regulators, and healthcare systems are rethinking what…
Switzerland Switzerland is the 22nd biggest country in Europe in terms of population yet plays host to a full 20 percent of the continent’s life science companies, with over 1,000 operational firms. Over 0.5 percent of the entire Swiss population (48,000 out of 8.8 million) work in the life sciences, 67…
Switzerland Intricacy, precision, and quality. These are bywords for Switzerland’s world-renowned watchmaking industry, but which could equally apply to its biopharmaceutical manufacturing footprint. As with top-end models from Rolex, Tag Heuer, or Breitling, made-in-Switzerland pharmaceuticals do not necessarily come cheap, but the country’s network of life science manufacturers seem content that…
Switzerland Jörg Storre, General Manager of CSL Vifor Pharma Switzerland, explores the company’s historical legacy and current focus on innovative iron therapies and nephrology. Storre highlights some of his strategic priorities, including improving patient care and access, fostering talent development, and maintaining supply security within a competitive landscape. When employees…
Switzerland Dr Isabelle Dahinden, General Manager of CSL Behring Switzerland, introduces the company’s unique history and strategic focus on plasma-derived treatments. Dr. Dahinden also discusses CSL Behring’s strong presence in Switzerland, including their extensive R&D, production capabilities, and partnerships, while touching on the challenges of navigating the Swiss healthcare landscape. …
Global 2023 was a tumultuous year for the pharma industry, with much wailing and gnashing of teeth from executives over the Inflation Reduction Act in the US as well as updated EU pharma legislation in Europe. Those companies producing COVID-19 vaccines and therapeutics saw revenues return to normal levels while others…
UAE Thanks to favourable regulations from the Ministry of Health and Prevention (MoHaP) which include fast-track regulatory pathways, patients in the UAE are gaining access to innovative medicines in similar time frames to their counterparts in the US and Europe, in some cases even ahead. Against this backdrop, the representatives of…
UAE With cutting-edge hospital infrastructure being put in place, government authorities rolling out evermore supportive regulatory upgrades, big pharma championing ‘clinical trial diversity’ with greater non-Caucasian representation in trial cohorts, and a high regional prevalence of genetic diseases, it seems that the stage is set for the UAE to assume a…
See our Cookie Privacy Policy Here
